MMP-13 Selective Alpha-sulfone Hydroxamates: Identification of Selective P1\u27 Amides by Fobian, Yvette M. et al.
Loyola University Chicago
Loyola eCommons
Chemistry: Faculty Publications and Other Works Faculty Publications
5-15-2011
MMP-13 Selective Alpha-sulfone Hydroxamates:
Identification of Selective P1' Amides
Yvette M. Fobian
Pfizer Research & Development
John N. Freskos
Pfizer Research & Development
Thomas E. Barta
Pfizer Research & Development
Louis J. Bedell
Pfizer Research & Development
Daniel Becker
Loyola University Chicago, dbecke3@luc.edu
Author Manuscript
This is a pre-publication author manuscript of the final, published article.
This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has been accepted for inclusion in
Chemistry: Faculty Publications and Other Works by an authorized administrator of Loyola eCommons. For more information, please contact
ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
© 2011 Elsevier
Recommended Citation
Fobian, Yvette M.; Freskos, John N.; Barta, Thomas E.; Bedell, Louis J.; and Becker, Daniel. MMP-13 Selective Alpha-sulfone
Hydroxamates: Identification of Selective P1' Amides. Bioorganic & Medicinal Chemistry Letters, 21, 10: , 2011. Retrieved from
Loyola eCommons, Chemistry: Faculty Publications and Other Works, http://dx.doi.org/10.1016/j.bmcl.2011.03.095
MMP-13 Selective α-Sulfone Hydroxamate Flexible Chain P1’ Amides
John N. Freskos, Yvette Fobian, Thomas E. Barta, Heintz, James R. Kiefer, Brent V. Mischke, 
Patrick Mullins, Grace E. Munie, Daniel P. Becker
Abstract: Continuing our interest in designing compounds preferentially potent and selective for 
MMP-13, we report on a series of hydroxamic acids with a flexible amide P1’ substituents. We 
identify an amide which spares both MMP-1 and -14, and shows >500 fold selectivity for 
mmp-13 vs. MMP-2 and -8.
Matrix Metalloproteinases (MMPs) are a family of about 27 zinc-dependent enzymes responsible 
for the turnover of collagen in connective tissue. There are a variety of disease states where 
degradation of collagen contributes to the pathology, specifically, in osteo- and rheumatoid 
arthritis; in tumor angiogenesis and metastasis; and in post-MI cardiovascular remodeling.1 In 
spite of the promise that modulation of MMP activity offers, the road from proof of concept to 
pharmacy shelves has been a long one. Clinical compounds often induce a dose-limiting joint-
stiffening often referred to as musculoskeletal syndrome (MSS).
It has been hypothesized that inhibition by drug candidates of MMP-1, a constitutive enzyme 
involved in the turnover of type II collagen, contributes to MSS.2a Sparing MMP-1 may not be 
sufficient. In our earlier research we saw that dosing with the MMP-1 sparing hydroxamate 1 
(SC-276, Figure 1) eventually led to joint stiffening.2b MT1-MMP (MMP-14) may also play a 
role in MSS, since it has been observed that MMP-14 knockout mice suffer from joint lesions 
reminiscent of the changes in MSS.3 The actual situation may be even more complex; MMP 
inhibitors that spare both MMP-1 and -14 may bind to members of the structurally-related 
ADAMs family (A Disintegrin And Metalloprotease),4 leading to undesired joint effects.
An alternative approach toward realizing efficacious MMP inhibitors with reduced side effects is 
to focus on optimizing the inhibition of the single MMP isoform that should confer the most 
therapeutic benefit, reducing the probability of off-target protease inhibition. MMP-13 is an 
attractive isoform to pursue; MMP-13  rapidly degrades type II collagen and is associated with 
pathology. The isoform is upregulated in osteoarthritic joints and in cancer.5 Structural studies 
show that MMP-13 differs from other MMP's in the depth of its S1' pocket, suggesting that 
lengthier inhibitors may confer selectivity.
With this in mind, we previously reported a series of rigid piperidino- ketones (compound 2, 
Figure 1) with  lengthier P1' subunits and, with optimization, we achieved significant selectivity 
for MMP-13 vs. other MMP isoforms.6,7 Although potent and selective, ketones like 2 exhibited 
poor PK, so we endeavored to improve their ADME properties, in part, though reduction of 
molecular weight. Conceptually dissecting the piperidine ring in compound 2 led to acyclic-
chain analogs such as ketone 3a (Figure 1).
The synthesis of ketone 3a and related ketones (e.g. 3b, Scheme 1) proceeded from aryl fluoride 
4,8 which was reacted with an omega benzyloxy 1-alkanol. The benzyl alcohol could be cleaved 
by hydrogenation and the resulting alcohol oxidized to a carboxylic acid. This acid, 6, was 
converted using EDC coupling to a Weinreb amide9 and the t-butyl ester was  treated with TFA to 
liberate the acid on the left hand side of the molecule, and this acid was coupled with THPONH2. 
Excess aryl Grignard and subsequent treatment with HCl led to the final product, 3b. Similar 
straightforward chemistry could be used to arrive at amides like 16a.
Isomeric amides (Scheme 2) could be obtained using, for example, tert-butyl N-(3-
hydroxypropyl)carbamate, which could be carried on to amine 9. Amine 9 was converted to 
amide analogs 10, and on to final hydroxamic acids 12a.
We synthesized over 500 extended chain amides and ketones in our MMP-13 program and the 
findings foe selected analogs are summarized in Table 1. Isonipecotate 2 demonstrates excellent 
selectivity for MMP-13 vs. the other MMP isoforms tested. The direct open-chain analogs of 2, 
ketones 13, 14, and 3a, which differ in connecting chain length, are each are more potent toward 
MMP-13 than isonipecotate 2. Compounds 14 and 3a achieve encouraging selectivity ratios for 
MMP-13 vs. MMP-8, -9, -1, and -14, but exhibit poor selectivity with respect to MMP-2. 
We looked at different linkers. Ether-linked compounds, like 17, lacked MMP-13/-2 selectivity.
 Amide analogs 15a and 16 show a significant dimunition of selectivity, with 16 being essentially 
equipotent for -8 and -13. N-Methylation, to alter the steric environment, did not improve the 
ratios, as can be seen from 15c and 15d. 
The benzamides of Scheme 2  looked significantly more attractive; compound 12b, for example, 
is potent for MMP-13, but unlike some of our earlier compounds spares MMP-2. Compounds 
12a and 12c also had desirable profiles. Conjugation of the amide π system into the aryl ring 
may diminish the conformational mobility of these amides vs. the amides of Scheme 1 (e.g. 12c 
vs 15a) and this might account for the improved selectivity of the latter series. In general, the 
electronics of ring substitution did not have a pronounced effect on potency/selectivity, but more 
hindered  analogs, such as 12d, saw a drop off in activity. We also looked at "non-aryl" amides, 
including 12e and 12f, and the compounds tested showed reduced  potency and/or selectivity.
Benzamides like 12a and 12c became the focus of further study, and, while we achieved 
meaningful levels of MMP-13 selectivity, we did not find amides that had both high potency and 
acceptable PK properties. Compound 12a had a half-life in rats of 0.58 h (BA 1.5%), presumably 
due to in vivo amide hydrolysis, and that was typical of the series. To address this issue, non-
hydrolyzable bioisosteric replacements for the amide linkage were sought, as reported in the 
following Letter.
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Figure 1. MMP inhibitors. Compound 1 spares 
MMP-1; Compounds 2 and 3 are MMP-13 selective.  
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Scheme 1. Reagents and Conditions: (a) X (1.05 
eq), NaH 1.2 (eq), 0°C-r.t., 4 h. (b) 5% Pd/C (wet), 
80 psi, THF, 1.5 h quant. (c) 2.5% RuCl3, NaIO4 (3 
eq), CCl4, water, quant (d) triethylamine (6.0 eq), N-
hydroxybenzotriazole (1.5 eq), HN(Me)OMe (3.0 
eq), EDC (1.4), DMF, 16 h (e) trifluoroacetic acid, 
triturate  (f) triethylamine (2.1 eq), N-
hydroxybenzotriazole (3.0 eq), THPONH2 (3.0 eq), 
EDC (1.2 eq), DMF, 3.5 h 40°C, rt 16 h (g) 4-
(MeO)PhMgBr (5 eq), THF, 0°C-rt overnight, then 
NH4Cl (h) 4N HCl, dioxane, MeOH, triturate (i) N-
methylmorpholine (2.1 eq), N-hydroxybenzotriazole 
(1.2 eq), anisidine (1.5 eq), EDC (1.5 eq), DMF, rt.
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Table 1: MMP selectivity of studied compounds
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a. For each compound, MMP-1 and MT1-MMP
> 5000, except for 1, where MT1-MMP = 8 nM.
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Scheme 2. Reagents and Conditions: (a) tert-butyl 
N-(3-hydroxypropyl)carbamate (1.1 eq), NaH (1.2 
eq), DMF, 0°C, 18 h (b) 4N HCl/dioxane, 1 h (c) 
DMF, triethylamine (1.2 eq), anisoyl chloride (1.2 
eq) (d) trifluoroacetic acid, 3 h, conc. at 50°C, 
quant. (e) N-methylmorpholine (2.1 eq), N-
hydroxybenzotriazole (1.2 eq), THPONH2 (1.5 eq), 
EDC (1.5 eq), DMF, 3 days (f)  4N HCl. dioxane, 
MeOH, 1 h, conc., triturate
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